News

• 25 Feb, 2022
  Spago Nanomedical får klartecken att inkludera patienter med pankreascancer i den kliniska studien SPAGOPIX-01
• 23 Feb, 2022
  Spago Nanomedical publishes the annual report for 2021
• 23 Feb, 2022
  Spago Nanomedical publicerar årsredovisningen för 2021
• 2 Feb, 2022
  Spago Nanomedical bokslutskommuniké januari-december 2021
• 2 Feb, 2022
  Spago Nanomedical year-end report January-December, 2021
• 25 Jan, 2022
  Signifikant minskad tumörtillväxt med Tumorad® enligt nya prekliniska resultat
• 25 Jan, 2022
  Significantly reduced tumor growth with Tumorad® according to new preclinical results
• 13 Jan, 2022
  Spago Nanomedicals phase 1 study with SpagoPix shows clear contrast enhancement and is expanded into new indications
• 13 Jan, 2022
  Spago Nanomedicals fas 1-studie med SpagoPix visar tydlig kontrast och utökas till nya indikationer
• 6 Dec, 2021
  Tumorad® shows good safety in preclinical studies